Eli Lilly is now the second drugmaker to propose a rebate model for 340B drug price discounts — and the second to ...
Wolfe Research initiated coverage of Eli Lilly (LLY) with an Outperform rating and $1,000 price target The company has lost over $100B in ...
Here's why the Vanguard Utilities ETF (NYSEMKT: VPU), Vanguard Consumer Staples ETF (NYSEMKT: VDC), and Vanguard Health Care ...
Hims & Hers Health Inc. shares tumbled 22% Thursday, on concerns that Amazon.com Inc.'s latest push into healthcare will disrupt Hims & Hers' business.
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...
Meanwhile, Hims & Hers tackles the GLP-1 shortage with a new app; Eli Lilly releases data on tirzepatide efficacy; 23andMe faces privacy concerns; and more.
Nektar continues to make progress with rezpegaldesleukin, with results from phase 2 atopic dermatitis study expected in H1'25 ...
Eli Lilly and Co. plans to set up a $31 million digital health innovation hub in Singapore, expanding its research and ...
Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...
Dublin-based NIBRT focuses on manufacturing. It provides training and research ... like the Spokes Project that saw SSPC and ...
With promising Phase 1 results in hand, Metsera hopes to develop a longer-lasting GLP-1 injection along with other types of ...
BioCrossroads has named Eli Lilly CEO, Dave Ricks, the recipient of the 2024 August M. Watanabe Life Sciences Champion of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback